Emily Menendez

GU Oncology Now

The single-arm, phase 2 SAKK 06/17 trial <a href="https://ascopubs.org/doi/abs/10.1200/JCO.23.00363" target="_blank" rel="noopener">analyzed the addition of neoadjuvant durvalumab to gemcitabine/cisplatin chemotherapy</a> in patients with muscle-invasive bladder cancer (MIBC) followed by radical surgery and adjuvant checkpoint inhibition with durvalumab.The study analyzed 54 cisplatin-fit patients with stage cT2-T4a cN0-1 operable MIBC from 12 treatment sites. Patients were administered 4 cycles of neoadjuvant gemcitabine/cisplatin combined with 4 cycles of durvalumab (starting at the second gemcitabine/cisplatin cycle) followed by radical surgery. Adjuvant durvalumab was administered for 10 cycles. The primary end point was event-free survival (EFS) at 2 years.The median follow-up was 40 months. The primary end point was met, with an EFS at 2 years of 76% (one-sided 90% CI [lower bound], 67%; two-sided 95% CI, 62-85). EFS at 3 years was 73% (95% CI, 59-83). Complete pathologic response in resected patients (n=52) was achieved in 17 patients (33%), and 31 (60%) had pathologic response &lt;ypT2 ypN0.Overall survival (OS) was 85% (95% CI, 72-92) at 2 years and 81% (95% CI, 67-89) at 3 years. Grade 3 and 4 treatment-related adverse events (TRAEs) during neoadjuvant treatment occurred in 42% and 25% of patients, respectively. Grade 3 TRAEs related to adjuvant durvalumab occurred in 5 (11%) patients, and grade 4 TRAEs occurred in 2 (4%).Adding perioperative durvalumab to the standard-of-care treatment of gemcitabine/cisplatin in patients with resectable MIBC resulted in high EFS and OS at 2 years.

Primary Analysis of Gemcitabine, Cisplatin Plus Neoadjuvant Durvalumab in MIBC

Muscle Invasive Urothelial Carcinoma

Adding perioperative durvalumab to gemcitabine/cisplatin in patients with resectable MIBC resulted in high EFS and OS at 2 years.

Gemcitabine, Cisplatin, and Neoadjuvant Durvalumab for MIBC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe